Pre-procedure oral rabeprazole administration for the prevention of bleeding after endoscopic submucosal dissection for gastric neoplasms

Pre-procedure oral rabeprazole administration for the prevention of bleeding after endoscopic submucosal dissection for gastric neoplasms - Oral PPI for preventing ESD bleeding

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011487

Enrollment

100

Registered

2013-08-14

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

oral PPI administration endoscopic submucosal dissection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The indication for gastric ESD was well or moderately differentiated adenocarcinoma of any size without ulceration or signs of submucosal invasion. Even if biopsy of the lesion led to a diagnosis of adenoma, it was determined that ESD was indicated when it met one of the following criteria: more than 2 cm diameter, reddish color, depressed lesion, and increasing size.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had received acid-suppressive drugs up to one week before pre-ESD endoscopy or Helicobacter pylori (Hp) eradication, or if they had a history of gastrectomy, major organ failure, or a drug allergy for PPI

Design outcomes

Primary

Measure	Time frame
post-ESD bleeding rate	—

Secondary

Measure	Time frame
change in gastric pH	—

Countries

Japan

Contacts

Public ContactTakuto Hikichi

Fukushima Medical University Hospital Department of Endoscopy

takuto@fmu.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026